Gaisl et al84 intranasally administered the TASK-1 and TASK-3 blocker BAY2253651 but with no effect on the severity of OSA as measured by the apnea-hypnopnea index (AHI) in patients with moderate to severe OSA. Here, KCNK9 is linked to obstructive sleep apnea syndrome.